Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in shape more than enough to tolerate FCR therapy, may still be superior candidates with the latter, While using the benefit becoming this therapy could be accomplished in 6 months while ibrutinib should be taken indefinitely. This option could be specially valuable for non-c… Read More